The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't ...

Immunoengineering, which has been beneficial to other medical specialties, could be used in the infectious diseases field to ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...

Major players operating in the carvykti market are Johnson & Johnson Services Inc., Legend Biotech, and Novartis AG. North America was the largest region in the carvykti market in 2024. Asia-Pacific ...

The Phase 1 trial, fully funded by a U.S. Department of Defense grant awarded to Cleveland Clinic, is nearing enrollment completion. Monitoring and data analysis will continue over the next three to ...

During a live event, Jack Khouri, MD, discusses selinexor-based therapies for relapsed multiple myeloma, emphasizing AE ...

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced the presentation of preclinical data on its in vivo CAR-T product candidate, SAIL-0804, ...

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...

Patients with lower physical function before starting daratumumab therapy showed greater treatment benefit than those who ...